TXA 709
Alternative Names: TXA-709Latest Information Update: 28 Feb 2024
At a glance
- Originator TAXIS Pharmaceuticals
- Class Antibacterials; Small molecules
- Mechanism of Action Bacterial FtsZ protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Methicillin-resistant Staphylococcus aureus infections; Staphylococcal infections
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Staphylococcal-infections in USA (IV)
- 28 Aug 2022 No recent reports of development identified for phase-I development in Methicillin-resistant-Staphylococcus-aureus-infections in Australia (PO)
- 28 Aug 2022 No recent reports of development identified for preclinical development in Staphylococcal-infections in USA (PO)